Vol.

No.

May 29, 2020May 29, 2020

Free

DOWNLOAD THE PDF

Ramon Parsons: How Mount Sinai did good science amid the COVID-19 deluge

Cover Story

Conversation with The Cancer Letter COVID-19 & Cancer Free

Ramon Parsons: How Mount Sinai did good science amid the COVID-19 deluge

By Paul Goldberg

The first COVID-19 patient walked into a Mount Sinai ER on March 1.

COVID-19 & Cancer Free Guest Editorial

CCC19 data point to extensive use of hydroxychloroquine, azithromycin, or both, by patients with cancer and COVID-19

By Otis W. Brawley

COVID-19 & Cancer Free

Radiation oncology appointments plummeted in the COVID-19 pandemic—but seem to be rising again

By Alexandria Carolan

Conversation with The Cancer Letter COVID-19 & Cancer Free

John Cleveland: How Moffitt will heal from conflict of interest trauma—and from COVID-19

By Matthew Bin Han Ong

COVID-19 Updates

Study: Hydroxychloroquine doesn't improve survival in hospitalized COVID-19 patients, but tocilizumab does

Genentech begins phase III trial of tocilizumab + remdesivir in hospitalized patients with severe COVID-19 pneumonia

UMich develops app that calculates risk of delaying cancer care during COVID-19

ACS CAN survey: cancer patients increasingly face COVID-19 health impact

In Brief

Catherine Alfano, Stacy Sanchez, Joseph Herman, Martin Karpeh recruited by Northwell Cancer Institute

Pamela Hull joins Markey as associate director of population science and community impact

Clinical Roundup

AI could predict risk of lung cancer recurrence

Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma

Fox Chase researchers investigate perceived barriers to discussing sexual issues in breast cancer patients

Evidence from two studies demonstrates efficacy of Immunoscore

MK-6482 induced positive response in Hippel-Lindau disease–associated kidney cancer

Drugs & Targets

Opdivo + Yervoy receive FDA approval combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC

Brigatinib receives FDA approval for ALK-positive metastatic NSCLC

CLR 131 receives fast track designation in lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Ramon Parsons: How Mount Sinai did good science amid the COVID-19 deluge

CCC19 data point to extensive use of hydroxychloroquine, azithromycin, or both, by patients with cancer and COVID-19

Radiation oncology appointments plummeted in the COVID-19 pandemic—but seem to be rising again

John Cleveland: How Moffitt will heal from conflict of interest trauma—and from COVID-19

COVID-19 Updates

Study: Hydroxychloroquine doesn't improve survival in hospitalized COVID-19 patients, but tocilizumab does

Genentech begins phase III trial of tocilizumab + remdesivir in hospitalized patients with severe COVID-19 pneumonia

UMich develops app that calculates risk of delaying cancer care during COVID-19

ACS CAN survey: cancer patients increasingly face COVID-19 health impact

In Brief

Catherine Alfano, Stacy Sanchez, Joseph Herman, Martin Karpeh recruited by Northwell Cancer Institute

Pamela Hull joins Markey as associate director of population science and community impact

Clinical Roundup

AI could predict risk of lung cancer recurrence

Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma

Fox Chase researchers investigate perceived barriers to discussing sexual issues in breast cancer patients

Evidence from two studies demonstrates efficacy of Immunoscore

MK-6482 induced positive response in Hippel-Lindau disease–associated kidney cancer

Drugs & Targets

Opdivo + Yervoy receive FDA approval combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC

Brigatinib receives FDA approval for ALK-positive metastatic NSCLC

CLR 131 receives fast track designation in lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login